Shots:
- Remegen has reported P-III trial data assessing telitacicept vs PBO in pts with primary Sjögren’s syndrome
- Trial met its 1EP of reduced EULAR Sjögren’s syndrome disease activity index (ESSDAI), showing improved disease activity at Wk. 24; NMPA’s BLA submission is planned, along with presentation of detailed data at an upcoming conference
- Telitacicept is a fusion protein that inhibits BlyS (BAFF) and APRIL, reducing autoreactive B cells and autoantibody production in autoimmune diseases
Ref: PRNewsWire | Image: Remegen | Press Release
Related News:- Greywolf Therapeutics Reports First Patient Dosing in P-I/II (EAST-1) Trial of GRWD0715 for Axial Spondyloarthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
